Last reviewed · How we verify
Vehicle of ADX-102 Ophthalmic Drops
Vehicle of ADX-102 Ophthalmic Drops is a ROS scavenger / Antioxidant Small molecule drug developed by Aldeyra Therapeutics, Inc.. It is currently in Phase 3 development for Dry eye disease, Allergic conjunctivitis. Also known as: Vehicle of Reproxlap.
This is a vehicle formulation (inactive carrier system) for ADX-102, designed to deliver the active pharmaceutical ingredient to the ocular surface.
This is a vehicle formulation (inactive carrier system) for ADX-102, designed to deliver the active pharmaceutical ingredient to the ocular surface. Used for Dry eye disease, Allergic conjunctivitis.
At a glance
| Generic name | Vehicle of ADX-102 Ophthalmic Drops |
|---|---|
| Also known as | Vehicle of Reproxlap |
| Sponsor | Aldeyra Therapeutics, Inc. |
| Drug class | ROS scavenger / Antioxidant |
| Target | Reactive oxygen species (ROS) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
ADX-102 is a reactive oxygen species (ROS) scavenger that reduces oxidative stress in ocular tissues. The vehicle formulation optimizes drug delivery, stability, and tolerability of ADX-102 when administered as ophthalmic drops to the eye.
Approved indications
- Dry eye disease
- Allergic conjunctivitis
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease (PHASE2, PHASE3)
- A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (PHASE1, PHASE2)
- SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis. (PHASE3)
- A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease (PHASE2)
- The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. (PHASE3)
- A Study of ADX-102 in Subjects With Allergic Conjunctivitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle of ADX-102 Ophthalmic Drops CI brief — competitive landscape report
- Vehicle of ADX-102 Ophthalmic Drops updates RSS · CI watch RSS
- Aldeyra Therapeutics, Inc. portfolio CI
Frequently asked questions about Vehicle of ADX-102 Ophthalmic Drops
What is Vehicle of ADX-102 Ophthalmic Drops?
How does Vehicle of ADX-102 Ophthalmic Drops work?
What is Vehicle of ADX-102 Ophthalmic Drops used for?
Who makes Vehicle of ADX-102 Ophthalmic Drops?
Is Vehicle of ADX-102 Ophthalmic Drops also known as anything else?
What drug class is Vehicle of ADX-102 Ophthalmic Drops in?
What development phase is Vehicle of ADX-102 Ophthalmic Drops in?
What are the side effects of Vehicle of ADX-102 Ophthalmic Drops?
What does Vehicle of ADX-102 Ophthalmic Drops target?
Related
- Drug class: All ROS scavenger / Antioxidant drugs
- Target: All drugs targeting Reactive oxygen species (ROS)
- Manufacturer: Aldeyra Therapeutics, Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease
- Indication: Drugs for Allergic conjunctivitis
- Also known as: Vehicle of Reproxlap
- Compare: Vehicle of ADX-102 Ophthalmic Drops vs similar drugs
- Pricing: Vehicle of ADX-102 Ophthalmic Drops cost, discount & access